Haemonetics Management
Management criteria checks 3/4
Haemonetics' CEO is Chris Simon, appointed in May 2016, has a tenure of 9.92 years. total yearly compensation is $10.72M, comprised of 10.3% salary and 89.7% bonuses, including company stock and options. directly owns 0.71% of the company’s shares, worth $19.58M. The average tenure of the management team and the board of directors is 4 years and 8.4 years respectively.
Key information
Chris Simon
Chief executive officer
US$10.7m
Total compensation
| CEO salary percentage | 10.26% |
| CEO tenure | 9.9yrs |
| CEO ownership | 0.7% |
| Management average tenure | 4yrs |
| Board average tenure | 8.4yrs |
Recent management updates
Recent updates
HAE: Pipeline And Product Updates Will Offset Cautious Sector Repricing
Haemonetics' implied fair value price target has been revised to $64 from $70 as analysts factor in updated sector peer multiples, adjustments to revenue growth and margin assumptions, and a slightly higher discount rate following recent Street research updates. Analyst Commentary Recent Street research around Haemonetics reflects a more cautious tone as several bearish analysts trim their price targets and revisit their assumptions on growth, margins, and valuation risk.
HAE: Vivasure Acquisition Will Support Earnings Quality Despite Sector Repricing
Haemonetics' updated fair value estimate has edged down by about $1, reflecting analysts' recent trims to price targets across the medical technology group, even as they point to healthy sector fundamentals and mixed revisions following the Vivasure acquisition. Analyst Commentary Recent research views on Haemonetics highlight a split between analysts who see upside from the Vivasure acquisition and those who are resetting expectations across the medical technology group after recent sector volatility.HAE: Vivasure Deal And Pipeline Progress Will Support Future Share Recovery
Analysts have reduced the Haemonetics fair value estimate to $70 from $74. Recent target resets in the group, including Citi's move to $70, reflect updated assumptions around growth, margins and the P/E multiple for the stock.HAE: Vivasure Deal And 2026 Outlook Will Support Earnings Quality
Analysts have modestly adjusted their views on Haemonetics, with several firms trimming price targets by $10 to $18 and one small $1 upward revision. These changes reflect updated assumptions on valuation multiples, while fair value and key model inputs remain broadly unchanged.HAE: Vivasure Acquisition And FY26 Outlook Will Support Margin Recovery
The analyst price target for Haemonetics has been reduced by $3.70, with analysts pointing to a slightly higher discount rate, a lower fair value estimate and some pressure on projected profit margins, even as they continue to apply a higher forward P/E and updated revenue growth assumptions in their models. Analyst Commentary Recent Street research on Haemonetics has been mixed, with several firms trimming their price targets while at least one firm has lifted its target in connection with the Vivasure Medical acquisition.HAE: Vivasure Acquisition Will Drive Execution And Support Future Share Recovery
Analysts have trimmed their fair value estimate for Haemonetics to about $74.00, reflecting mixed Street price target moves that weigh recent target cuts from several firms against at least one increase tied to a favorable view of the Vivasure Medical acquisition. Analyst Commentary Recent Street research around Haemonetics reflects a split view, with several bearish analysts trimming price targets and a smaller group seeing upside tied to the Vivasure Medical acquisition.HAE: Vivasure Deal And Buyback Will Shape Execution And Share Recovery
Analysts have lifted their price target for Haemonetics from about $58 to roughly $74.82, citing recent Street research that points to higher assumed revenue growth, slightly stronger profit margins, a higher future P/E, and supportive views on the Vivasure acquisition and recent earnings execution. Analyst Commentary Recent Street research has centered on two main themes for Haemonetics, the Vivasure acquisition and the company’s latest earnings print.Haemonetics: Re-Rating Complete, Time To Cash In
Jan 11HAE: Achievable Hospital Reset And FY26 Outlook Will Support Gradual Recovery
Narrative Update on Haemonetics Analysts have inched up their price target for Haemonetics, with updated fair value rising from about US$90 to roughly US$92, citing recent price target increases, company performance that met or exceeded expectations across segments, and what they view as more achievable guidance and improved credibility on execution and messaging. Analyst Commentary Recent commentary has focused on how Haemonetics is executing against expectations, how realistic its guidance looks, and what that might mean for valuation support and potential growth in the medium term.These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
Jan 06
HAE: Achievable Hospital Guidance Reset Will Support Gradual Share Recovery
Analysts have modestly raised their price target on Haemonetics to approximately $90 from about $86, citing stronger than expected execution across all segments, a more achievable Hospital guidance reset, and an improved long term sales outlook that supports higher growth and valuation assumptions. Analyst Commentary Analysts see the recent quarter as a constructive inflection point for Haemonetics, with improved guidance and execution supporting a modestly higher valuation framework, though some caution remains around sustainability of growth and delivery against new targets.HAE: Broad Outperformance And Achievable Hospital Guidance Will Support Gradual Share Recovery
Analysts have modestly raised their price target on Haemonetics to approximately $86 from about $85, citing broad-based outperformance, more achievable Hospital guidance, and an upgraded FY26 sales outlook that supports a gradual recovery in the shares. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the price target increase toward the high $80s reflects growing confidence in the company’s ability to sustain outperformance across all operating segments.HAE: Solid Execution And Achievable Guidance Will Support Measured Share Recovery
Analysts have raised their price target for Haemonetics from $83 to approximately $84.55. They cite solid execution, an improved sales outlook, and increased confidence in the company's guidance and operational credibility.HAE: Upbeat Execution And Reset Guidance Should Drive Share Price Recovery
Haemonetics' analyst price target has been raised from $76.27 to $83.00, as analysts cite improved execution, strong segment performance, and a more optimistic sales outlook as key drivers for the upward revision. Analyst Commentary Following recent quarterly results and the revised price target, analysts have shared both optimistic highlights and points of caution regarding Haemonetics' outlook and valuation.A Piece Of The Puzzle Missing From Haemonetics Corporation's (NYSE:HAE) 36% Share Price Climb
Nov 07Execution Challenges Will Shift Outlook For Global Plasma And Hemostasis Expansion
Haemonetics’ analyst price target has been revised lower by analysts to approximately $76 from $77. This change reflects concerns about execution within the Interventional Technologies segment, despite confidence in the company’s long-term value.Aging Demographics Will Expand Global Plasma And Hemostasis Markets
The analyst price target for Haemonetics has been lowered by approximately $1.73 to $76.91. Analysts cite ongoing concerns around sales execution and challenges in the Interventional Technologies segment.Is Haemonetics Corporation (NYSE:HAE) Trading At A 48% Discount?
Sep 15Aging Demographics Will Expand Global Plasma And Hemostasis Markets
The decrease in Haemonetics' price target primarily reflects a significant reduction in consensus revenue growth forecasts, partially offset by improved net profit margin expectations, leading to a revised fair value of $85.18. What's in the News Haemonetics Corporation (NYSE:HAE) added to Russell 2000 Dynamic Index Valuation Changes Summary of Valuation Changes for Haemonetics The Consensus Analyst Price Target has fallen from $92.45 to $85.18.Market Cool On Haemonetics Corporation's (NYSE:HAE) Earnings Pushing Shares 27% Lower
Aug 08Haemonetics (NYSE:HAE) Seems To Use Debt Quite Sensibly
Jun 30Market Participants Recognise Haemonetics Corporation's (NYSE:HAE) Earnings
Jun 10Do Haemonetics' (NYSE:HAE) Earnings Warrant Your Attention?
May 10Is Haemonetics (NYSE:HAE) Using Too Much Debt?
Mar 18Haemonetics: Almost Blood In The Streets
Feb 20Haemonetics (NYSE:HAE) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Feb 13Investors Interested In Haemonetics Corporation's (NYSE:HAE) Earnings
Dec 06These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
Sep 09
Innovative Express Plus Technology And Strategic Market Expansion Set To Propel Revenue Growth
Innovation and R&D in Blood Management Technologies, including new products, are expected to increase market share and net margins through product differentiation.What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E
Aug 14Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?
Jul 18Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Jun 21Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?
Apr 30Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion
Apr 12Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Mar 07Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Mar 06The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business
Feb 15The Price Is Right For Haemonetics Corporation (NYSE:HAE)
Jan 01Haemonetics: Solid Performance Of This Blood Play
Nov 22Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today
Nov 14Is Haemonetics (NYSE:HAE) A Risky Investment?
Oct 24Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment
Oct 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 27 2025 | n/a | n/a | US$175m |
| Sep 27 2025 | n/a | n/a | US$168m |
| Jun 28 2025 | n/a | n/a | US$163m |
| Mar 29 2025 | US$11m | US$1m | US$168m |
| Dec 28 2024 | n/a | n/a | US$130m |
| Sep 28 2024 | n/a | n/a | US$124m |
| Jun 29 2024 | n/a | n/a | US$115m |
| Mar 30 2024 | US$12m | US$1m | US$118m |
| Dec 30 2023 | n/a | n/a | US$127m |
| Sep 30 2023 | n/a | n/a | US$128m |
| Jul 01 2023 | n/a | n/a | US$137m |
| Apr 01 2023 | US$11m | US$1m | US$115m |
| Dec 31 2022 | n/a | n/a | US$96m |
| Oct 01 2022 | n/a | n/a | US$86m |
| Jul 02 2022 | n/a | n/a | US$68m |
| Apr 02 2022 | US$9m | US$945k | US$43m |
| Jan 01 2022 | n/a | n/a | US$23m |
| Oct 02 2021 | n/a | n/a | US$31m |
| Jul 03 2021 | n/a | n/a | US$64m |
| Apr 03 2021 | US$9m | US$963k | US$79m |
| Dec 26 2020 | n/a | n/a | US$108m |
| Sep 26 2020 | n/a | n/a | US$106m |
| Jun 27 2020 | n/a | n/a | US$96m |
| Mar 28 2020 | US$9m | US$937k | US$77m |
Compensation vs Market: Chris's total compensation ($USD10.72M) is above average for companies of similar size in the US market ($USD7.12M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Simon (61 yo)
9.9yrs
Tenure
US$10,722,488
Compensation
Mr. Christopher A. Simon, also known as Chris, has been the Chief Executive Officer and President of Haemonetics Corporation since May 16, 2016 and has been its Director since May 2016. He joined Haemoneti...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.9yrs | US$10.72m | 0.71% $ 19.6m | |
| CFO, Executive VP & Financial Officer | 4yrs | US$2.98m | 0.030% $ 835.0k | |
| Executive VP | 9.1yrs | US$2.79m | 0.066% $ 1.8m | |
| Executive VP & Chief Commercial Officer | 3.5yrs | US$2.20m | 0.0083% $ 227.9k | |
| Executive VP & COO | 1yr | no data | no data | |
| VP, Chief Accounting Officer & Principal Accounting Officer | 3.5yrs | no data | 0.00089% $ 24.4k | |
| Senior Director of Investor Relations | 6.5yrs | no data | no data | |
| Senior Vice President of Strategy & Corporate Development | 3yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | 4.7yrs | no data | 0.042% $ 1.2m | |
| Senior VP & Chief Medical Officer | 3yrs | no data | no data | |
| President of Plasma Business Unit | 8.6yrs | no data | no data | |
| Senior Manager of Investor Relations | no data | no data | no data |
4.0yrs
Average Tenure
54yo
Average Age
Experienced Management: HAE's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.6yrs | US$10.72m | 0.71% $ 19.6m | |
| Independent Director | 8.5yrs | US$294.95k | 0.043% $ 1.2m | |
| Independent Director | 6yrs | US$282.95k | 0.023% $ 619.2k | |
| Independent Chairman | 8.3yrs | US$449.95k | 0.031% $ 853.9k | |
| Independent Director | 7yrs | US$289.95k | 0.026% $ 706.4k | |
| Independent Director | 20.3yrs | US$279.95k | 0.047% $ 1.3m | |
| Independent Director | 11.8yrs | US$302.95k | 0.043% $ 1.2m | |
| Independent Director | 4.7yrs | US$282.95k | 0.017% $ 474.1k | |
| Member of Scientific Advisory Council | no data | no data | no data | |
| Member of Scientific Advisory Council | no data | no data | no data | |
| Member of Scientific Advisory Council | no data | no data | no data | |
| Member of Scientific Advisory Council | no data | no data | no data |
8.4yrs
Average Tenure
71yo
Average Age
Experienced Board: HAE's board of directors are considered experienced (8.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 22:26 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/27 |
| Annual Earnings | 2025/03/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Haemonetics Corporation is covered by 28 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Alexander Paris | Barrington Research Associates, Inc. |
| Gary Prestopino | Barrington Research Associates, Inc. |